Ventilator-Associated Pneumonia

New or worsening oxygenation impairment, purulent endotracheal secretions, fever or leukocytosis, and a new or progressive infiltrate should trigger a focused VAP assessment, but no single clinical feature reliably establishes the diagnosis. Clinical diagnosis remains inaccurate, and approximately one quarter to one third of patients with clinically suspected VAP may have true infection. BMJ+1BMJDiagnostic importance of pulmonary interleukin-1 ... - ThoraxBMJDiagnostic importance of pulmonary interleukin-1β and ...

At the bedside, first identify instability requiring immediate management: escalating oxygen or ventilator support, shock, or rapidly progressive respiratory failure should prompt prompt pneumonia-directed antimicrobial therapy after respiratory sampling when this does not delay treatment. Simultaneously reassess noninfectious and alternative infectious causes of infiltrates and hypoxemia, because false-positive VAP diagnoses expose patients to unnecessary antibiotic toxicity and selection of resistant organisms. Nature+1NatureVentilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges | Nature CommunicationsPubMedVentilator-associated pneumonia in the ICU - PMC

Send a lower-respiratory specimen before or at antibiotic initiation when feasible. Endotracheal aspirate sampling is less invasive than bronchoscopic techniques; evidence comparing BAL or protected specimen brush with endotracheal aspirate has not shown reductions in mortality, ICU length of stay, or duration of mechanical ventilation. NatureNatureVentilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges | Nature Communications

Interpret respiratory cultures against the full trajectory: changing oxygenation, secretion burden, leukocyte count, chest radiography, and response to therapy are components used in a Day 10 clinical-cure framework. Persistent or recurrent deterioration despite active therapy should prompt reassessment for an untreated pathogen, inadequate drug exposure, a nonpulmonary source, or a noninfectious pulmonary process rather than automatic antibiotic extension. BMJBMJassociated pneumonia biomarker evaluation (VIBE) study: ...

Quantitative microbiology can refine probability but does not resolve diagnostic uncertainty. In one ICU research definition, bacterial pneumonia required a positive quantitative culture above 100 CFU/mL, bacterial PCR from BAL fluid, or a positive urine antigen in the appropriate clinical setting; this is a study definition, not a universal treatment threshold. NatureNatureCircuits between infected macrophages and T cells in SARS-CoV-2 pneumonia | Nature

BAL neutrophil percentage, quantitative culture burden, and pathogen genomic load are being evaluated as predictors of VAP treatment failure, but these biomarkers should not yet replace standard clinical and microbiologic assessment. BMJ+1BMJVentilator-associated pneumonia biomarker evaluation ...BMJassociated pneumonia biomarker evaluation (VIBE) study: ...

For a patient with high clinical probability of VAP, select empiric antibiotics using the local ICU antibiogram, prior respiratory isolates, recent antibiotic exposure, and risk for multidrug-resistant organisms. Early VAP, defined in one review as occurring within 4 days of intubation, is more often attributed to antibiotic-susceptible pathogens, whereas VAP emerging after 4 days is more often associated with multidrug-resistant bacteria; use this as a risk modifier rather than a stand-alone rule. PubMedPubMedVentilator-associated pneumonia in the ICU - PMC

Once microbiology and susceptibility data return, de-escalate to the narrowest active regimen and align treatment duration with clinical and bacteriologic progress. This limits resistance, adverse effects, and toxicity from empiric broad-spectrum therapy. PubMedPubMedVentilator-associated pneumonia in the ICU - PMC

Do not select tigecycline for VAP when suitable alternatives exist. The FDA label reports that a hospital-acquired pneumonia trial, including ventilator-associated pneumonia, failed to demonstrate efficacy; among ventilator-associated pneumonia patients, mortality was 19.1% with tigecycline versus 12.3% with comparator treatment. accessdata fda+1accessdata fda211158Orig1s000 | FDA - accessdata.fda.govaccessdata fda[PDF] 4139875 This label may not be the latest approved by FDA. For ...

Monitor oxygenation and ventilator requirements, endotracheal secretion burden, white blood cell count, and chest radiography after initiating treatment. A clinical-cure framework at Day 10 requires survival without planned comfort-only care plus either discontinuation of pneumonia antibiotics without recurrence within 48 hours or continued therapy with stable or improved pneumonia signs and symptoms. BMJBMJassociated pneumonia biomarker evaluation (VIBE) study: ...

Failure to stabilize or improve should trigger a diagnostic reset: review whether the recovered organism is susceptible to the selected regimen, whether the respiratory sample represents colonization, and whether another pulmonary or extrapulmonary process better explains the deterioration. The absence of a universally accepted VAP reference standard means discordance between clinical and microbiologic findings is common. NatureNatureVentilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges | Nature Communications

Escalating to repeat BAL, quantitative culture, or advanced biomarker testing should be selective. Quantitative cultures have not demonstrated improvement in mortality, ICU stay, mechanical-ventilation duration, or antibiotic-change rates compared with qualitative cultures, so invasive sampling is most useful when it is expected to alter a specific management decision. NatureNatureVentilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges | Nature Communications

Apply evidence-based hospital practices intended to prevent pneumonia in ventilated patients and reassess the continuing need for invasive ventilation, because VAP is defined by its occurrence after prolonged mechanical ventilation. Current guideline-based prevention practices are used in hospitalized patients, although specific bundle components should follow institutional protocols. NEJM+1NEJMHealth Care–Associated Infections in U.S. Hospitals, 2023 ...ScienceDirectVentilator-Associated Pneumonia - an overview

Inhaled amikacin has been studied as a preventive intervention: among patients mechanically ventilated for at least 3 days, a subsequent 3-day course reduced the burden of VAP. This finding supports consideration only within a protocolized prevention strategy; it does not establish inhaled amikacin as treatment for established VAP or replace standard prevention practices. NEJMNEJMInhaled Amikacin to Prevent Ventilator-Associated ...

Do not confuse prevention with indiscriminate antimicrobial exposure. Antibiotic overuse in suspected VAP contributes to resistance and toxicity; prevention programs should preserve diagnostic stewardship and prompt de-escalation when VAP is not confirmed clinically. PubMedPubMedVentilator-associated pneumonia in the ICU - PMC